Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and Tolerability Study of PEP in Healthy Adults
NCT06429033Phase 1Completed
- Sponsor
- Clinical Testing of Beverly Hills
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of purified exosome product, sponsored by Clinical Testing of Beverly Hills. Primary endpoints: Dose Limiting Toxicities at 14 days, Maximum Tolerated Dose at 14 days and 5 more. Started Apr 2025; status: completed.
02
Drugs
purified exosome product
Beyond the preview
Go deeper on NCT06429033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06429033.